Two hormones. One weekly injection.
Tirzepatide works with two naturally occurring hormones — GIP and GLP-1 — to regulate blood sugar, control appetite, and support sustainable weight management.
The dual pathway at work
Follow the journey of a single once-weekly injection as it activates complementary metabolic pathways.
Tirzepatide Injection
Once-weekly subcutaneous injection
GIP Activation
Amplifies insulin secretion
GLP-1 Activation
Reduces glucagon & appetite
Improved Glucose Control
Lower HbA1c, stable sugars
Reduced Appetite
Greater satiety, fewer cravings
Weight Management
Meaningful, sustained reduction
Understanding the two pathways
GIP — Glucose-dependent Insulinotropic Polypeptide
Tirzepatide is the first dual agonist to include GIP receptor activation. GIP amplifies glucose-dependent insulin secretion and enhances the body's ability to store nutrients efficiently, contributing to superior glucose lowering.
GLP-1 — Glucagon-Like Peptide-1
GLP-1 receptor activation reduces glucagon release, slows gastric emptying, and acts on the brain to reduce appetite and increase satiety. These effects help lower caloric intake and support weight reduction.
Together, GIP and GLP-1 drive superior results
The complementary actions of both hormones result in superior glucose lowering and greater weight reduction compared with conventional GLP-1 receptor agonists alone — supporting better treatment outcomes across the patient journey.
Take the First Step Toward a Healthier Future
MEPTIDE is a prescription medicine. Talk to your doctor to determine whether Tirzepatide is appropriate for your glycemic control and weight-management goals.
Individual results vary. Always follow your healthcare provider's guidance.